Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study

Completed · Phase 4

Conditions studied: Schizophrenia

In brief

Patients with schizophrenia are much more likely to be engaged in smoking and other addictive behaviors, possibly related to biochemical abnormalities in the reward center of the brain. The primary purpose of the present study is to investigate whether switching patients with schizophrenia to a new atypical antipsychotic, aripiprazole, a drug with a novel mechanism of action, will have an impact on smoking behavior.

Key facts

Study ID

NCT00167817

Run by

Veterans Medical Research Foundation

People needed

15

Starts

2003-07-01

Expected to finish

2005-09-01

Last updated by the study team

2007-04-19

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Schizophrenia, on stable antipsychotic dose for at least one month
• Ages 18-65 inclusive
• Overweight (body mass index of 25 kg/m2 or greater)
• Daily cigarette smoker (by self-report)

You may not qualify if…

• Inability to provide informed consent
• Treatment refractory schizophrenia
• Current treatment with clozapine
• Current antipsychotic polypharmacy which may preclude monotherapy with aripiprazole
• Documented poor compliance with oral antipsychotic medication

Where it is running

• VA San Diego Healthcare System — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.